-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Public Policy
Latest From Public Policy
BIO CEO: Patient Groups Join Call for Data Protection
Biomedical innovation is not only key to our industry’s future, but more importantly, continued medical breakthroughs are vital to patients living with debilitating diseases and their families. Without ongoing progress in our industry, patients of today and tomorrow have limited hope for future cures and therapies.
For July 4: Let’s Thank the Inventors
My hope for America this July 4? I hope, in 100 years, the response time to human and environmental suffering will be immediate. Until that day arrives (thanks to scientific breakthroughs funded by individual citizens) — let’s thank our scientists, investors, and inventors who work and play around us.
Finally, let’s also thank the founding fathers for knowing America’s innovative potential without seeing it for themselves.
Twitter Twang: July 1st
Twitter Twang: July 1st
Twitter Twang: June 30th
Here’s this morning’s Twitter Twang!
Holman: Follow-on Biologics Bill Threatens Innovation By Weakening Patent Rights
Chris Holman, Professor at the University of Missouri-Kansas City School of Law and author of Holman’s Biotech IP Blog, recently posted a great summary of the patent provisions in the follow-on biologics bill currently under consideration in Congress.
